Biotech IPO revival faces competition from cash-rich big pharma buyers
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC